The Burrill Report
News
Biotech Dealmaking Gets off to a Strong Start in 2012 February 01, 2012 | Press Release
Burrill & Company Announces Close of Burrill Brazil Fund I January 18, 2012 | Press Release
David Wetherell Joins Burrill & Company Venture Capital Group as Managing Director January 06, 2012 | Press Release
See all News
Marietta Wu
Director, TaiwanPrior to joining Burrill, Dr. Wu held professional positions with Edwards Lifesciences and Eli Lilly & Company. She was Director of Strategy at Edwards, responsible for the strategic planning in the biologics program. At Eli Lilly & Company Oncology and Integrated Biology, Dr. Wu oversaw finance, business development, pipeline valuation, organizational restructure and outsourcing strategy. She also worked at Eli Lilly’s M&A Group and with Oncology Discovery Research. Dr. Wu founded BioHorizon, a consultancy focused on value creation in the life sciences industry across the Pacific Rim. She advised a number of biotech start-ups and venture capital firms.
Dr. Wu’s scientific expertise centers on basic and clinical research in oncology and neuroscience. She was selected by Nobel Laureate Dr. Marshall Nirenberg as an IRTA Fellow at the National Institutes of Health (NIH). Dr. Wu received her M.D. from Shanghai Second Medical University, a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Business School.


